Puma Biotech (PBYI) Licensing Partner CANbridge Pharmaceuticals Receives Registration Approval in Hong Kong for NERLYNX

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to Puma Biotech (PBYI) Licensing Partner CANbridge Pharmaceuticals Receives Registration Approval in Hong Kong for NERLYNX

Puma Biotech (PBYI) Tops Q3 EPS by 59c, Revenues Miss

November 6, 2019 6:03 PM EST

Puma Biotech (NASDAQ: PBYI) reported Q3 EPS of ($0.12), $0.59 better than the analyst estimate of ($0.71). Revenue for the quarter came in at $56.4 million versus the consensus estimate of $60.4 million.

In the third quarter of 2019 we were pleased to report that our supplemental New Drug Application for neratinib for the treatment of third-line HER2-positive metastatic breast cancer was accepted by the... More